You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).
This information has recently been updated and is now available.
Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN (Warfarin Sodium) for Injection Due to Presence of Particulate Matter
07/01/2014 11:34 AM EDT
Bristol-Myers Squibb Company (NYSE:BMY) is voluntarily recalling six lots of COUMADIN FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company's investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples.